Drug Profile


Latest Information Update: 20 Jul 2001

Price : $50

At a glance

  • Originator MIGENIX
  • Class Antibacterials
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Staphylococcal infections

Most Recent Events

  • 20 Jul 2001 Discontinued-I for Staphylococcal infections in USA (Intranasal)
  • 14 Aug 2000 Phase-I clinical trials for Staphylococcal infections in USA (Intranasal)
  • 04 Aug 2000 Results of a clinical study have been added to the Bacterial infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top